Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Otsuka Forms JV with Turkey’s No. 1 Drug Maker, Set to Launch Samsca in 2013
November 7, 2012
- Tolvaptan Suppresses Rate of Increase in Total Kidney Volume by 50%: Otsuka
November 7, 2012
- Eli Lilly Japan, Chugai to Terminate Comarketing Agreement for Evista
November 7, 2012
- Takeda to Buy Envoy of US to Reinforce Drug Discovery Prowess
November 7, 2012
- Ono Achieves Target Reduction of Sales Ratio of Long-Listed Drugs to Mid-50% Level: President Sagara
November 7, 2012
- Generic Sales Ratio Exceeds 80% for First Time in Interim Results: Nippon Chemiphar
November 6, 2012
- Abbott Splits into Two Companies; Research-Based Pharmaceuticals, Diversified Medical Products
November 6, 2012
- Abbott Japan Spins Off New Drug Biz, Establishes New Firm “AbbVie”
November 6, 2012
- Sawai’s Status Improved Within Mediceo by Utilizing ARs
November 6, 2012
- Asahi Kasei Pharma 1st Half Sales Show Significant Growth, Teribone May Exceed Peak Sales in 1st Year
November 6, 2012
- Astellas Logs Sales of 25.5 Bil. Yen in Oncology Sector, Investments Bearing Fruit: Pres. Hatanaka
November 5, 2012
- Shionogi Enjoys Sales, Profit Growth in 1st Half, 8 Strategic Products Make Up 50% of Japan Sales
November 5, 2012
- Domestic Drug Makers’ Major Products See Sharp Declines in 1st Half; Sales of Aricept, Lipitor Down 30%
November 5, 2012
- Eisai to Go on Offensive for Aricept by Introducing Consultation Date Reminder Service for Patients: President Naito
November 5, 2012
- Astellas Discontinues Development of SGLT-2 Inhibitor Ipragliflozin in Europe, US; Development in Japan to Go Forward
November 5, 2012
- Astellas: Slight Sales Decline in 1st Half due to Strong Yen, Domestic Sales Virtually Unchanged
November 5, 2012
- “Lecture Meeting Fever” as Companies Seek New Ways to Interact with Doctors Under Tougher Restrictions on Settai
November 5, 2012
- Medipal HD Reports Sharp Increase in Operating Profits in First Half
November 2, 2012
- Eisai Suffers Double-Digit Sales, Profit Falls in 1st Half as Mainstay Drugs Slump
November 2, 2012
- Sales Target for Prasugrel Achievable Despite Add’l Indication Dropped: Daiichi Sankyo Pres. Nakayama
November 2, 2012
ページ
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…